Treatment options for metastatic melanoma have improved significantly in the past five years with the development of targeted therapies and immunotherapies [10], but studies demonstrate a lower response rate to immunotherapy when compared to cutaneous melanoma [11]. Due to the availability of targeted therapies, BRAF mutations should be investigated, although they occur less frequently in mucosal than in cutaneous melanomas [4,11]. This evidence concerns the gene BRAF and cutaneous melanoma.